While biosimilar makers have long established themselves in Europe, only a few copycat versions of biologics have launched in the nascent US market, which is beginning to show signs of maturing, but is complicated by a reimbursement landscape fractured by multiple players. The spotlight on drug pricing, however, may at long last provide the catalyst for change.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,